查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1672819

流感疫苗市场按疫苗类型、疫苗效力、接种途径、年龄层、技术、分销管道和地区划分

Influenza Vaccines Market, By Vaccine Type, By Valency, By Route of Administration, By Age Group, By Technology, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 197 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2025 年全球流感疫苗市场规模估计为 89.1 亿美元，预计到 2032 年将达到 145.9 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 7.3%。

报告范围 报告详细信息
基准年 2024 2025 年市场规模 89.1亿美元
效能资料 2020-2024 预测期 2025-2032
预测期：2025 年至 2032 年复合年增长率 7.30% 2032 年金额预测 145.9亿美元
数字。 2025 年流感疫苗市场占有率（按地区划分）
流感疫苗市场-IMG1

几十年来，流感疫苗接种一直是预防性保健的重要组成部分。流感病毒经常发生变异和演化，因此每年都需要开发更新的疫苗。疫苗透过增强人体对变异病毒的免疫反应发挥作用。该疫苗旨在针对 3 至 4 种病毒株（取决于特定流感季节使用的疫苗类型）提供免疫力，这些病毒株是透过监测和其他科学研究确定的，在即将到来的流感季节最有可能在任何特定地区传播。过去几年，全球流感疫苗市场一直稳步增长，这得益于人们对季节性疫苗接种认识的不断提高、新技术的采用、医疗机构的疫苗接种指南的不断扩大以及世界各国政府的支持不断增加。

市场动态

全球流感疫苗市场的成长受到多种因素的推动，例如流感疫情的加剧、国际卫生组织制定的疫苗接种指南的采用率不断提高、疫苗接种意识的增强、新产品的推出、对重组疫苗的偏好增加以及主要企业的地理覆盖范围不断扩大。然而，开发四价流感疫苗所涉及的高昂研发成本、新疫苗核准所需的严格监管准则以及由于流感病毒株抗原漂移而出现的疫苗抗药性都是阻碍市场成长的一些障碍。市场相关人员在医疗基础设施不断改善、可支配收入不断上升的新兴经济体中看到了机会。製造商也致力于开发一种能够对多种流感病毒株提供持久保护的通用疫苗。

研究的主要特点

  • 本报告对全球流感疫苗市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
  • 它还强调了各个领域的潜在商机并解释了该市场的有吸引力的投资提案矩阵。
  • 它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
  • 它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，介绍了全球流感疫苗市场的主要企业概况。
  • 本报告的见解将使负责人和企业经营团队能够就未来产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
  • 全球流感疫苗市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
  • 透过全球流感疫苗市场分析中使用的各种策略矩阵，相关人员将更容易做出决策。

目录

第一章 调查目的与前提条件

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告描述
    • 市场定义和范围
  • 执行摘要
  • 一致的机会图 (COM)

第三章市场动态、法规与趋势分析

  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 影响分析
  • 产业趋势
  • 监管情景
  • 最近的产品核可/发布
  • PEST分析
  • 波特的分析

4. 全球流感疫苗市场-冠状病毒 (COVID-19) 大流行的影响

  • 对需求的影响
  • 对医疗保健的影响
  • 流行病学

5. 2020 年至 2032 年全球流感疫苗市场（按疫苗类型划分）（十亿美元）

  • 介绍
  • 惰性
  • 减毒活疫苗

6. 2020 年至 2032 年全球流感疫苗市值（单位：十亿美元）

  • 介绍
  • 四价
  • 三价

7. 2020 年至 2032 年按给药途径分類的全球流感疫苗市场（十亿美元）

  • 介绍
  • 注射
  • 鼻腔喷剂

8. 2020-2032 年全球流感疫苗市场（按年龄层划分）（十亿美元）

  • 介绍
  • 孩子们
  • 成人

9. 2020 年至 2032 年全球流感疫苗市场（依技术划分）（十亿美元）

  • 介绍
  • 鸡蛋流感疫苗
  • 细胞培养流感疫苗
  • 重组流感疫苗

10. 2020-2032 年全球流感疫苗市场按分销管道划分（十亿美元）

  • 介绍
  • 公共
  • 私人的

第 11 章。 2020-2032 年全球流感疫苗市场（按地区划分）（十亿美元）

  • 介绍
  • 北美洲
  • 拉丁美洲
  • 欧洲
  • 亚太地区
  • 中东
  • 非洲
  • 南非
  • 中部非洲
  • 北非

第十二章 竞争格局

  • 热图分析
  • 市场占有率分析
    • CSL Seqirus
    • GlaxoSmithKline plc
    • Sanofi
    • AstraZeneca
    • FluGen, Inc.
    • Moderna, Inc.
    • Biocryst Pharmaceuticals Inc.
    • CPL Biologicals Pvt. Ltd.
    • CureVac AG
    • OSIVAX
    • Solaris Vaccines
    • Pfizer
    • Daiichi Sankyo
    • Bharat BIoTech
    • Sinovac BIoTech
    • Solaris Vaccines

第 13 章 分析师观点

  • 兴衰
  • 一致的机会地图

第 14 章 参考文献与调查方法

  • 参考
  • 调查方法
简介目录
Product Code: CMI1705

Global Influenza Vaccines Market is estimated to be valued at USD 8.91 Bn in 2025 and is expected to reach USD 14.59 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.3% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 8.91 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 7.30% 2032 Value Projection: USD 14.59 Bn
Figure. Influenza Vaccines Market Share (%), By Region 2025
Influenza Vaccines Market - IMG1

Influenza vaccines have been an important element of preventive healthcare for decades. The influenza viruses have the ability to mutate and evolve regularly, necessitating the development of updated vaccines each year. The vaccines work to boost the body's immune response to these changing viruses. They are designed to immunize against the three or four strains (depending on the vaccine type used for a particular flu season) that surveillance and other scientific studies have determined are most likely to be in circulation for the upcoming flu season in any given region. The global influenza vaccines market has witnessed steady growth over the past few years due to the growing awareness about seasonal vaccination, introduction of novel technologies, expansion of vaccination guidelines by healthcare organizations, and rising government support worldwide.

Market Dynamics:

The global influenza vaccines market growth is driven by various factors such as the increasing prevalence of influenza, growing adoption of vaccination guidelines set by international health organizations, rising awareness about vaccination, new product launches, growing preference for recombinant technology vaccines, and expansion in geographical reach of major players. However, the market growth can be challenging due to high R&D costs involved for development of quadrivalent influenza vaccines, stringent regulatory guidelines for approval of new vaccines and vaccine resistance arising due to antigenic drift of influenza virus strains. The market players see opportunities in emerging countries owing to improving healthcare infrastructure and rising disposable incomes. Manufacturers are also working on the development of universal influenza vaccine with durable protection against multiple flu strains.

Key Features of the Study:

  • This report provides an in-depth analysis of the global influenza vaccines market, and provides market size (USD BN) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global influenza vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study includes Seqirus, GlaxoSmithKline plc, Sanofi, AstraZeneca, FluGen Inc., Moderna Inc., Biocryst Pharmaceuticals Inc., CPL Biologicals Pvt. Ltd., CureVac AG, OSIVAX, Solaris Vaccines, Pfizer, CSL, Daiichi Sankyo, Bharat Biotech, and Sinovac Biotech.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global influenza vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global influenza vaccines market.

Market Segmentation

  • Vaccine Type:
    • Inactivated
    • Live Attenuated
  • Valency:
    • Quadrivalent
    • Trivalent
  • Route of Administration:
    • Injection
    • Nasal Spray
  • Age Group:
    • Pediatrics
    • Adults
  • Technology:
    • Egg-Based Flu Vaccines
    • Cell Culture-Based Flu Vaccines
    • Recombinant Flu Vaccines
  • Distribution Channel:
    • Public
    • Private
  • Regional:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Seqirus
    • GlaxoSmithKline plc
    • Sanofi
    • AstraZeneca
    • FluGen Inc.
    • Moderna Inc.
    • Biocryst Pharmaceuticals Inc.
    • CPL Biologicals Pvt. Ltd.
    • CureVac AG
    • OSIVAX
    • Solaris Vaccines
    • Pfizer
    • CSL
    • Daiichi Sankyo
    • Bharat Biotech
    • Sinovac Biotech

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Vaccine Type
    • Market Snapshot, By Valency
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Age Group
    • Market Snapshot, By Technology
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunity
  • Impact Analysis
  • Key Developments
  • Industry Trends
  • Regulatory Scenario
  • Recent Product Approval/Launches
  • PEST Analysis
  • Porter's Analysis

4. Global Influenza Vaccines Market- Impact of Coronavirus (COVID-19) Pandemic

  • Impact on Demand
  • Impact on Healthcare
  • Epidemiology

5. Global Influenza Vaccines Market, By Vaccine Type, 2020 - 2032, (USD BN)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Inactivated
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD BN)
  • Live Attenuated
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

6. Global Influenza Vaccines Market, By Valency, 2020 - 2032, (USD BN)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Quadrivalent
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD BN)
  • Trivalent
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

7. Global Influenza Vaccines Market, By Route of Administration, 2020 - 2032, (USD BN)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Injection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD BN)
  • Nasal Spray
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

8. Global Influenza Vaccines Market, By Age Group, 2020 - 2032, (USD BN)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Pediatrics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD BN)
  • Adults
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD BN)

9. Global Influenza Vaccines Market, By Technology, 2020 - 2032, (USD BN)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Egg-Based Flu Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD BN)
  • Cell Culture-Based Flu Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD BN)
  • Recombinant Flu Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD BN)

10. Global Influenza Vaccines Market, By Distribution Channel, 2020 - 2032, (USD BN)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Public
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD BN)
  • Private
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD BN)

11. Global Influenza Vaccines Market, By Region, 2020 - 2032 (USD BN)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032(%)
    • Y-o-Y Growth Analysis, For Regions, 2020 - 2032
    • Regional Trends
  • North America
    • Market Size and Forecast, By Vaccine Type, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Valency, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Age Group, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Technology, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Country, 2020 - 2032 (USD BN)
      • U.S.
      • Canada
  • Latin America
    • Market Size and Forecast, By Vaccine Type, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Valency, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Age Group, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Technology, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Country, 2020 - 2032 (USD BN)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Vaccine Type, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Valency, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Age Group, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Technology, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Country, 2020 - 2032 (USD BN)
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Vaccine Type, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Valency, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Age Group, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Technology, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Country, 2020 - 2032 (USD BN)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Vaccine Type, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Valency, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Age Group, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Technology, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Country, 2020 - 2032 (USD BN)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Vaccine Type, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Valency, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Age Group, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Technology, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032 (USD BN)
    • Market Size and Forecast, By Region/Country, 2020 - 2032 (USD BN)
  • South Africa
  • Central Africa
  • North Africa

12. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • CSL Seqirus
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • GlaxoSmithKline plc
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Sanofi
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • AstraZeneca
    • FluGen, Inc.
    • Moderna, Inc.
    • Biocryst Pharmaceuticals Inc.
    • CPL Biologicals Pvt. Ltd.
    • CureVac AG
    • OSIVAX
    • Solaris Vaccines
    • Pfizer
    • Daiichi Sankyo
    • Bharat Biotech
    • Sinovac Biotech
    • Solaris Vaccines

13. Analyst View

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

14. References and Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact